Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in Active Ankylosing Spondylitis
NCT03928743Phase 3Completed
- Sponsor
- UCB
- Start
- Apr 2019
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Bimekizumab with Placebo (2 arms). Primary endpoint: Assessment of SpondyloArthritis International Society 40% Response Criteria at 16 weeks. Started Apr 2019; status: completed.
02
Drugs
bimekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03928743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03928743.